Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

PHASE3CompletedINTERVENTIONAL
Enrollment

441

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Diabetes Mellitus
Interventions
DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.

DRUG

Glipizide

Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.

Trial Locations (80)

Unknown

Alexander City

Foothill Ranch

Huntington Park

Long Beach

Los Angeles

Redlands

Prospect

Bradenton

Fort Myers

Miami

Ormond Beach

Winter Park

Roswell

Aurora

La Porte

South Bend

Salisbury

Clarkston

Omaha

Hamilton

Albuquerque

Beachwood

Westlake

Zanesville

Bensalem

Aiken

Greenville

Greer

Taylors

Corpus Christi

Dallas

Pasadena

San Antonio

Tomball

Ogden

Salt Lake City

Budapest

Miskoic

Nyíregyháza

Karnāl

Bangalore

Belagavi

Mumbai

Ashkelon

Haifa

Holon

Nahariya

Rishon LeZiyyon

Safed

Aguascalientes

Saltillo

Durango

Pachuca

Morelia

Monterrey

Guadalajara

Mexico City

Nezahualcóyotl

Arequipa

Lima

Piura

Gdansk

Krakow

Warsaw

Baia Mare

Brasov

Bucharest

Galati

Satu Mare

Arkhangelsk

Irkutsk

Smolensk

Cape Town

Centurion

Durban

Johannesburg

Port Elizabeth

Pretoria

Donetsk

Kharkiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY